Summary of Roivant Sciences FY Conference Call Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: FY Conference Call on January 12, 2026 - **Speaker**: CEO Matt Gline Key Points Company Positioning and Strategy - Roivant is entering a new era with a significantly simplified business model focused on a smaller subset of products, emphasizing clinical execution and pipeline potential [3][4] - The company aims to shape its own destiny with a high priority on delivering results from its clinical programs [3] Financial Strength - Roivant reported a cash balance of **$4.4 billion**, positioning it well for future growth without the need for additional fundraising [5][9] - The company has a strong track record with **12 positive phase III studies** and **8 FDA approvals**, indicating robust past performance and a solid pipeline [9] Clinical Development Highlights - **Brepocitinib**: Positive data for dermatomyositis (DM) with plans to file an NDA by early 2026, marking it as the first novel oral therapeutic for DM [4][5] - **IMVT-1402**: Progressing in pivotal studies for Graves' disease, with expectations for significant disease-modifying benefits [4] - Upcoming data releases include registrational programs for brepocitinib in non-infectious uveitis (NIU) and phase IIb data for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) [6][7] Market Opportunities - The company sees a potential **$15 billion-plus portfolio** across various indications, with significant opportunities in DM, NIU, and Graves' disease [19][70] - Brepocitinib is expected to capture market share from existing therapies, particularly for patients currently on high-dose steroids or IVIG [41][42] Competitive Landscape - Roivant is positioned to be among the first non-prostacyclin novel mechanisms in PH-ILD, competing against established treatments [6][57] - The company is optimistic about the potential for brepocitinib to outperform existing treatments in DM, especially given the enthusiasm from physicians [41][46] Legal and Regulatory Environment - Ongoing litigation with Moderna regarding lipid nanoparticle technology, with a jury trial scheduled for March 2026 [5][60] - The outcome of this case may have implications for other ongoing litigations and the company's overall strategy [62] Future Outlook - Roivant anticipates a transformative next 36 months with multiple commercial launches and pivotal study readouts [11][19] - The company is focused on executing its clinical programs and expanding its pipeline to drive future value [19][29] Unique Business Model - Roivant's model combines talent from various backgrounds, emphasizing creative clinical development and a focus on delivering value to patients [10][30] - The company aims to differentiate itself by maintaining high standards for partnerships and transactions, driven by a focus on profitability [36] Conclusion - Roivant Sciences is positioned for significant growth with a strong financial foundation, a focused pipeline, and a commitment to innovative clinical development. The upcoming years are expected to be pivotal for the company as it seeks to capitalize on its opportunities in the biotech space [19][70]

If You Didn't Buy Roivant in 2025, Now Is the Time J.P. Morgan Healthcare Conference January 12, 2026 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial p ...

Core Insights - Roivant Sciences Ltd. (NASDAQ:ROIV) is highlighted as one of the best stocks under $25 to buy, with an increased price target of $32 from Leerink Partners, maintaining an Outperform rating due to lower estimated operational expenses and anticipated profitability starting in fiscal year 2029 [1] Group 1: Company Projections - By the end of 2028, Roivant's "Next 36 Month vision" includes expectations for at least three commercial launches, four or more NDA/BLA submissions, no less than eight crucial readouts, and at least three proof-of-concept evaluations [2] - The development schedules for Roivant's primary therapeutic candidates have been advanced, including brepocitinib, with a New Drug Application filing for dermatomyositis expected in early 2026 and a potential commercial launch in early 2027 [3] Group 2: Clinical Development - The Phase III trial for brepocitinib in non-infectious uveitis has achieved full enrollment ahead of schedule, with topline results anticipated in the second half of 2026 [3] - Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies, with clinical product candidates including IMVT-1402 for Graves' disease and difficult-to-treat rheumatoid arthritis [4]

Core Insights - Jefferies published an in-depth report focusing on the investment prospects of Roivant Sciences (ROIV.US), highlighting three key catalysts and valuation logic that could significantly impact the company's stock price by 2026 [1] Group 1: Key Catalysts - The first catalyst involves a patent lawsuit related to LNP technology with Moderna (MRNA.US) and Pfizer (PFE.US), with a trial set to begin on March 9, 2026. Conservative estimates suggest Roivant could receive $2-4.5 billion in damages based on a 5% royalty from total COVID-19 vaccine revenues of $60-130 billion [1] - The second catalyst is the Phase II clinical trial data for Pulmovant's PH-ILD treatment, which could lead to a Phase III trial if the data shows a reduction in pulmonary vascular resistance (PVR) of over 20%. The Phase III trial is expected to start in the first half of 2027, with results anticipated in 2030 [2] - The third catalyst is the Phase III trial data for Priovant's brepo drug, which has been moved up to the second half of 2026. If brepo captures 30-50% of the market for non-infectious uveitis (NIU) patients, peak sales could reach $1.5-3 billion [2] Group 2: Valuation Analysis - Jefferies utilized a sum-of-the-parts (SOTP) valuation method, estimating the expected compensation from the LNP lawsuit at $2.5-3 billion, with Roivant's share being $1.5-2 billion. The market value of the IMVT subsidiary is estimated at $5.4 billion, adjusted to $5.1 billion after accounting for cash [3] - The brepo drug is valued at $1.75 billion in peak sales, with a 5x price-to-earnings ratio and a 95% success rate, leading to a valuation of $6.25 billion for Roivant's stake [3] - Overall, the valuation framework indicates a clear picture, with current cash of $4.4 billion and projected cash of $3.7 billion, supporting a "buy" rating with a target price of $24, representing a 10.95% upside from the latest closing price of $21.63 [3]

Insider Selling Activity - Las Vegas Sands CEO Rob Goldstein 抛售近 2 million 股股票，价值超过 1.3 亿美元，其中包括行使 2028 年到期的期权 [1] - Roy Sciences 内部人士出售股票，投资者 Vivic Ramaswami 减持超过 3 million 股生物制药公司股票，价值约 68 million 美元，CEO 出售约 38 million 美元的股票 [2] - Varity 指出，Royant 的销售量激增，该公司股价接近历史高位 [2] - Nvidia 董事 Harvey Jones 出售 250,000 股股票，价值约 44 million 美元 [3] - VIA 首席行政官（即将离职）出售略低于 31,000 股股票，价值约 1 million 美元 [3] - Varity 指出，包括 CEO 在内的五位高管最近出售了股票，此前该股从 11 月中旬的多年低点反弹 [3] Stock Performance - Nvidia 股价本季度下跌近 3% [3]

Core Insights - The company is hosting its first Investor Day since 2022, highlighting significant progress made during this period [1][2] Group 1 - The head of Investor Relations expresses excitement about the company's journey and encourages participation from shareholders [2] - The management team will provide detailed insights into the company's developments and future plans [2] - Forward-looking statements will be made during the presentation, with a reminder for attendees to review filed information [3]

Roivant Sciences Investor Day Summary Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: 2025 Investor Day held on December 11, 2025 - **Context**: First Investor Day since 2022, highlighting significant progress and future plans [1][4] Key Points and Arguments Business Transformation - Roivant is undergoing a transformation, marking a new decade focused on simplified operations and the development and commercialization of promising programs [5][6] - The company emphasizes a shift from its previous decade, aiming for a more streamlined approach [6] Clinical Execution and Pipeline Opportunities - Roivant has made substantial progress in clinical milestones, with multiple pipeline programs showing potential for blockbuster indications [6][7] - The company has a well-capitalized position with $4.4 billion in cash and cash equivalents, allowing for funding into profitability [7][8] - Roivant has a strong track record with 12 positive phase three studies and eight FDA approvals, with three commercial launches anticipated [8][9] Unique Talent Model - The leadership team is primarily homegrown, fostering a unique organizational culture that emphasizes rapid adaptation and alignment of incentives with project success [9][10] Focus on Execution - Roivant is committed to executing clinical programs effectively, with recent updates indicating accelerated timelines for NDA filings and clinical data readouts [12][13][14] Commercial Opportunities - The company is targeting high-value indications with significant unmet medical needs, particularly in the areas of dermatomyositis (DM), non-infectious uveitis (NIU), and cutaneous sarcoidosis [16][17][18] - The commercial strategy is designed to capitalize on the current biotech landscape, focusing on tractable indications with limited competition [21][22] Specific Programs and Indications Brepocitinib (Brepo) - Brepo is a dual inhibitor of JAK1 and TYK2, with potential applications in DM, NIU, and cutaneous sarcoidosis [25][26] - The NDA filing for DM is expected by early 2026, with significant enthusiasm from the clinical community [12][26] - The NIU program is particularly promising, with a high unmet need and a market of potentially under 200,000 patients [33][34] Non-Infectious Uveitis (NIU) - NIU is a leading cause of blindness among working-age populations, necessitating aggressive treatment strategies [34][35] - The company has observed significant systemic therapy use among NIU patients, indicating a strong market opportunity for new therapies [39][40] Cutaneous Sarcoidosis - Roivant is pursuing cutaneous sarcoidosis as a significant indication, with a small proof-of-concept study underway [48][49] - The potential market includes around 40,000 patients in the U.S., with a high urgency for effective treatments [51][52] Financial Performance and Shareholder Value - Roivant has returned cash to shareholders since going public, increased its cash balance, and doubled its share price [18] - The company has repurchased $1.5 billion of stock since its IPO, with an additional $500 million authorized for buybacks [8][9] Market Context and Future Outlook - The current biotech environment presents unique opportunities for Roivant, with a shift towards successful commercialization of innovative therapies [20][21] - The company is well-positioned to navigate macroeconomic and regulatory changes, with a focus on executing its pipeline effectively [21][22] Conclusion - Roivant Sciences is poised for significant growth with a robust pipeline, strong financial backing, and a commitment to addressing high unmet medical needs in the biotech sector [6][7][8]

December 11, 2025 New York City Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, potential uses of cash and capital allocat ...

Core Insights - Roivant is at a transformational moment with opportunities for three major product launches, each representing a pipeline-in-a-product opportunity with blockbuster potential [2] - The company is hosting an Investor Day to discuss pipeline updates and long-term value creation strategies [1][9] Program-Specific Highlights and Updates - Brepocitinib is expected to have its NDA filing for dermatomyositis in early 2026, with a commercial launch anticipated in early 2027 [6][7] - The Phase 3 trial for brepocitinib in non-infectious uveitis is fully enrolled, with topline data expected in the second half of 2026 [6][7] - A proof-of-concept trial for brepocitinib in cutaneous sarcoidosis is also fully enrolled, with topline data expected in the first half of 2026 [6][7] - IMVT-1402's potentially registrational trial in difficult-to-treat rheumatoid arthritis is expected to provide topline data in 2026 [6][7] - The ongoing Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease is on track, with topline data expected in the second half of 2026 [5][8] Financial and Strategic Developments - Roivant's financing efforts alongside key institutional investors generated approximately $550 million for Immunovant, extending its cash runway to the launch of IMVT-1402 in Graves' disease [6][7] - The company is well-positioned to generate shareholder value through its late-stage pipeline and long-term strategy [2][6]

Company Overview - The company has undergone significant transformation in 2025, with positive developments stemming from strategic setups made in previous years [1] - The company is now valued at approximately $14.5 billion and operates as a public biopharma entity focused on late-stage drug development for underserved patient populations [2] Progress and Achievements - The company's portfolio has advanced meaningfully this year, contributing to heightened excitement and optimism within the organization [3]